Australia's top medical research body backs puberty blockers for trans youth
New interim advice from the NHMRC says puberty blockers should stay an option for some trans young people, decided together with families and clinicians. Queensland and the Northern Territory still have bans.

Australia's National Health and Medical Research Council (NHMRC) released interim advice on Monday saying puberty suppressants should remain a treatment option for trans and gender diverse people under 18 who have started puberty, have gender incongruence and are assessed as suitable.
The advice rests on shared decision-making: the young person, their parents or carers and their clinicians weigh the evidence, the possible benefits and harms, and the young person's own circumstances, then decide together. "Puberty suppressants are one possible part of care," said Prue Torrance, the NHMRC's acting chief executive.
Federal Health Minister Mark Butler asked for the review in 2025. He said treatment should come with proper information, a full health assessment, input from a multidisciplinary team and regular monitoring, and warned that some of the public debate "runs the risk of being quite damaging" to the mental health of young people and their families.
Advocates welcomed it. Equality Australia chief executive Anna Brown said the advice shows the care trans young people receive today "is grounded in evidence", and called on Queensland and the Northern Territory to lift their bans. The advice is open for public comment until 18 January 2027, and full draft national care standards are due for consultation in late 2027.